Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

Preliminary findings were presented at the 2025 ASCO Genitourinary Cancers Symposium. 2 Investigators reported that 71% of ...

Objectives To identify whether patients with arrhythmia, heart failure or ischaemic heart disease presenting with anxiety ...

First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA mo ...

Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable respon ...

TX45 APEX Phase 2 patient enrollment in PH-HFpEF is nearing completion with topline results anticipated in late Q4 2026 or early Q1 2027TX2100 advanced into Phase 1a healthy volunteer clinical trial ...

Two years ago, Jennifer Kirtley looked down at the scale and saw 328 pounds. Today, she’s looking in the mirror at a size 6.

Part A of LIGHTHOUSE Trial reinforce ATSN-201's favorable safety profile and durable structural and functional benefits in patients with X-linked retinoschisis ...

Mineralys (MLYS) was downgraded to Hold as the FDA NDA/PDUFA is set for lorundrostat, but trial misses and AstraZeneca ...

The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated ...

Objectives Body mass index (BMI) confers a higher risk of colorectal cancer (CRC) and may influence cancer diagnostic ...

As the abortion pill heads back to the Supreme Court, advocates have a backup that's effective and safe: misoprostol alone.